Medimmune Limited

Roland Bürli

Lutz Jermutus

Maria Herva

Damian C Crowther

Shawn Donald Johnstone

Ina Terstiege

Massimiliano Travagli

Johan Bartholomeus

Stephane Turcotte

Rebecca Jarvis

Thor Ostenfeld

In some embodiments, the disclosure provides for a conjugate comprising: a) a peptide that competes with an Fc fragment of an IgG for binding to an Fc receptor; and b) a targeting moiety that targets molecular aggregates. In some embodiments, the disclosure provides for methods of using the conjugates for treating a disease or disorder associated with aggregate formation.

Conjugates for targeting and clearing aggregates

The present application relates to compounds of formula (I') or formula (I), such as formula (Ia), and their pharmaceutical compositions/preparations. This application further relates to methods of treating or preventing neurodegenerative disorders, such as Alzheimer's disease (AD), Parkinson's disease (PD), Huntington disease (HD) and other CAG-triplet repeat (or polyglutamine) diseases, amyotrophic lateral sclerosis (ALS; Lou Gehrig's disease), diffuse Lewy body disease, chorea-acanthocytosis, primary lateral sclerosis, multiple sclerosis (MS), frontotemporal dementia, Friedreich's ataxia, acute head injury, and epilepsy (repression of microglia activation).

Small molecule modulators of the BTB domain of Keap1

Growing community of inventors

Cambridge, United Kingdom

Roland Bürli